Lymphomas & Lymphoid Neoplasia

Lymphomas & Lymphoid Neoplasia

A collection of features and news articles published in ASH Clinical News related to lymphomas and lymphoid neoplasia.

WIB_icon

Updates From ECHELON-1: Brentuximab Vedotin Provides Durable Efficacy in Hodgkin Lymphoma

Previously reported results from the phase III ECHELON-1 trial suggested that replacing bleomycin with brentuximab vedotin in the standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)...

Perspectives on 2019’s New Hematology Drug Approvals

In 2019, the FDA approved several new therapies – or new indications for previously approved therapies – for people living with blood disorders, including...

KTE-X19: A CAR T-Cell Option for Mantle Cell Lymphoma?

According to results from the ZUMA-2 trial presented at the 2019 ASH Annual Meeting, 93% of patients with relapsed/refractory mantle cell lymphoma (MCL) responded...

Bristol-Myers Wins $752 Million From Gilead in Patent Dispute

Bristol-Myers Squibb has won a $752 million lawsuit against Gilead Sciences to settle a U.S. patent dispute regarding the chimeric antigen receptor (CAR) T-cell...

Early-Phase Trial Shows Mosunetuzumab Induces Durable Complete Remissions in Patients With B-Cell Non-Hodgkin...

Watch our interview with Stephen J. Schuster, MD. The bispecific monoclonal antibody mosunetuzumab, which binds to CD3 and CD20, led to durable responses in patients...

FDA Approves Zanubrutinib for Relapsed/Refractory Mantle Cell Lymphoma

The FDA has granted accelerated approval to zanubrutinib, an inhibitor of Bruton tyrosine kinase (BTK), to treat adults with mantle cell lymphoma who have...

How Does Chemotherapy During Pregnancy Affect Outcomes in Patients With Hodgkin Lymphoma?

In patients diagnosed with Hodgkin lymphoma (HL) during pregnancy, antenatal chemotherapy is associated with increased preterm contractions and lower birthweight for newborns, according to...

Stephen Schuster: Mosunetuzumab Leads to Durable Complete Remissions in Non-Hodgkin Lymphoma

Patients with both indolent and aggressive non-Hodgkin lymphomas responded to treatment with the monoclonal antibody, even those whose disease had not responded to CAR...

DDGP Versus SMILE: Comparing Regimens for Extranodal Natural Killer T-Cell Lymphoma

In patients with extranodal natural killer T-cell lymphoma (ENKTL), treatment with the chemotherapy regimen of dexamethasone, cisplatin, gemcitabine, and peg-asparaginase (DDGP) improved survival compared...

Rajat Bannerji: REGN1979 Active Across Non-Hodgkin Lymphoma Subtypes

The bispecific antibody REGN1979 demonstrated efficacy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, with no observed dose-limiting toxicities. Rajat Bannerji, MD, PhD,...
Advertisement

Current Issue

January 2020 Annual Meeting Edition

This issue features highlights from the 2019 ASH Annual Meeting, reflections on physician wellness, and more.